Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc CRDL


Primary Symbol: T.CRDL

Healthcare
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc > March Corporate Presentation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Post by Youhillmanon Mar 03, 2021 9:05am
161 Views
Post# 32703244

March Corporate Presentation

March Corporate Presentation

Is posted on CRDL's website, link is attached below.

Also, I was somewhat surprised with yesterday's announcement regarding the NASDAQ listing as I thought this would occur during Q2 of this year after CRDL released news concerning Cortalex sales at Shoppers and or Phase One results of AM. 

Never the less they did, perhaps it was due to the momentum of the GW Pharma news.

Still looking forward to CRDL becoming a Billion Dollar Company after Covid trials are approved by the FDA in Q3!

https://www.cardiolrx.com/wp-content/uploads/2021/03/Cardiol-Therapeutics-Corporate-Presentation-March-2021-1.pdf

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities